Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
Zacks Investment Research9/25/2026Positive
REGN
Regeneron Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$81.13B
P/E Ratio
19.49
EPS
$40.44
Beta
0.19
52W High
$859.34
52W Low
$538.24
50-Day MA
$774.60
200-Day MA
$735.26
Dividend Yield
0.46%
Profit Margin
27.90%
Forward P/E
14.51
PEG Ratio
1.32
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Fundamentals
| Revenue (TTM) | $15.53B |
| Gross Profit (TTM) | $6.91B |
| EBITDA | $4.70B |
| Operating Margin | 33.10% |
| Return on Equity | 14.00% |
| Return on Assets | 6.53% |
| Revenue/Share (TTM) | $150.31 |
| Book Value | $316.11 |
| Price-to-Book | 2.60 |
| Price-to-Sales (TTM) | 5.22 |
| EV/Revenue | 4.839 |
| EV/EBITDA | 13.07 |
| Quarterly Earnings Growth (YoY) | -4.50% |
| Quarterly Revenue Growth (YoY) | 16.70% |
| Shares Outstanding | $101.14M |
| Float | $95.85M |
| % Insiders | 2.08% |
| % Institutions | 93.53% |
Historical Volatility
HV 10-Day
22.15%
HV 20-Day
27.21%
HV 30-Day
26.49%
HV 60-Day
30.51%
HV Rank
11.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($850.88 target)
4
Strong Buy14
Buy9
Hold1
Strong SellLatest News
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
GlobeNewsWire9/24/2026Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Seeking Alpha9/23/2026Neutral
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
Regeneron Pharmaceuticals NASDAQ: REGN executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch.
MarketBeat9/23/2026Positive
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.
MarketBeat9/15/2026Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/15/2026Neutral
REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action
SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.
PRNewsWire9/14/2026Neutral
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
GlobeNewsWire9/14/2026Neutral
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026
GlobeNewsWire9/13/2026Neutral
INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline
San Francisco, California--(Newsfile Corp. - September 11, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.
Newsfile Corp9/11/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on REGN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026